Crescent Biopharma (CBIO) Current Deferred Revenue (2013 - 2026)
Crescent Biopharma (CBIO) reported Current Deferred Revenue of $3.1 million for Q1 2026, down 25.0% quarter-over-quarter from $4.2 million in Q4 2025.
Crescent Biopharma (CBIO) Current Deferred Revenue (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 8 years of Current Deferred Revenue data on file, last reported at $3.1 million in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $3.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (changed N/A YoY), and the FY2025 annual result was $4.2 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $3.1 million in Q1 2026 per CBIO's latest filing, from $4.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $4.2 million in Q4 2025 and troughed at $3.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.12 Mn |
| Dec 31, 2025 | 4.16 Mn |
| Dec 31, 2018 | 98,771.00 |
| Sep 30, 2018 | 92,654.00 |
| Jun 30, 2018 | 86,637.00 |
| Mar 31, 2018 | 82,017.00 |
| Dec 31, 2017 | 78,028.00 |
| Sep 30, 2017 | 74,072.00 |
| Jun 30, 2017 | 70,598.00 |
| Mar 31, 2017 | 70,598.00 |
| Dec 31, 2016 | 68,551.00 |
| Sep 30, 2016 | 81,398.00 |
| Jun 30, 2016 | 81,398.00 |
| Jun 30, 2015 | 38,327.00 |
| Mar 31, 2015 | 67,965.00 |
| Dec 31, 2014 | 97,012.00 |
| Sep 30, 2014 | 115,050.00 |
| Jun 30, 2014 | 111,397.00 |
| Mar 31, 2014 | 107,686.00 |
| Dec 31, 2013 | 104,191.00 |